Evidence map›Paper›PMID 38206397›Full record

Observational studyEuropean journal of pediatrics2024

NT-proBNP course during MIS-C post-COVID-19: an observational study.

Saïd Bichali, Naïm Ouldali, François Godart, Patrice Maboudou, Ali Houeijeh, Stéphane Leteurtre

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Saïd BichaliPaediatric Cardiology, Univ. Lille, CHU Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France. said_b91@hotmail.fr.ORCID http://orcid.org/0000-0003-2220-6061
Naïm OuldaliGeneral Paediatrics, Univ. Paris, APHP CHU Robert Debré, Paris, France.
François GodartPaediatric Cardiology, Univ. Lille, CHU Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France.
Patrice MaboudouCentre de Biologie-Pathologie, Univ. Lille, CHU Lille, F-59000, Lille, France.
Ali HoueijehPaediatric Cardiology, Univ. Lille, CHU Lille, 2 Avenue Oscar Lambret, F-59000, Lille, France.
Stéphane LeteurtreULR 2694 - METRICS: Évaluation Des Technologies de Santé Et Des Pratiques Médicales, Univ. Lille, CHU Lille, F-59000, Lille, France.
Université de Lille · FRInserm · FR

Funding

ReCH-MIE Grant from the ministry of Health and Prevention n°RECHMIE-22-0004
6 · The paper itself

Abstract

Multisystem inflammatory syndrome in children (MIS-C or PIMS-TS) is a severe disease. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is used for positive and differential diagnosis, diagnosis of complications and severity, and cardiogenic shock prediction. However, contrasting cut-offs have been suggested. The aims of the present study were to compare NT-proBNP values depending on the time of measurement and to describe the NT-proBNP course during the MIS-C episode. The data from a single-centre cohort observational study on the impact of time to diagnosis, defined as the time from first symptom to diagnosis of MIS-C, were used for the purpose of this study, with an extended period of inclusion from May 2020 to April 2023. The timing and level of all NT-proBNP samples available for each patient were retrospectively collected. Thirty-seven children (18 (49%) females, median age 8.8 years, 14 (38%) with shock) were included. Until diagnosis, NT-proBNP increased with time and was significantly higher at 6 days from first symptoms than at 3 days (median (interquartile range) 32,933 (7773-61,592) versus 1994 (1291-4190) pg/mL, respectively, p = 0.031). From diagnosis, NT-proBNP decreased by at least 50% after 3.0 (2.1-5.3) days (n = 12) when NT-proBNP at diagnosis was low ≤ 11,000 pg/mL versus 1.8 (0.7-3.4) days (n = 16) when NT-proBNP at diagnosis was high (p = 0.040), and after 3.6 (2.4-5.9) days (n = 7) when fever persisted after 48 h versus 1.8 (0.8-3.0) days (n = 21) when fever resolved before 48 h (p = 0.004).  Conclusions: During the MIS-C episode, NT-proBNP increased over time until diagnosis and treatment. It dropped faster thereafter in children with high NT-proBNP at diagnosis > 11,000 pg/mL and slower in case of persistent fever. What is Known: • NT-proBNP is useful in MIS-C for positive and differential diagnosis, diagnosis of complications and severity, and cardiogenic shock prediction. • Contrasting cut-offs for differential diagnosis and severity assessment have been suggested. What is New: • Before diagnosis, NT-proBNP increases with time and is significantly higher at 6 days from first symptoms than at 3 days suggesting different cut-offs depending on the timing of measurement. • From diagnosis and treatment initiation, the 50% NT-proBNP drop occurs earlier in children with high NT-proBNP at diagnosis > 11,000 pg/mL and later in children with persistent fever.

Indexed as

COVID-19Heart FailureSystemic Inflammatory Response SyndromeBiomarkersChildFemaleHumansMaleNatriuretic Peptide, BrainPeptide FragmentsRetrospective StudiesShock, CardiogenicBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Brain natriuretic peptideCutoffDiagnostic delayHeart failurePaediatricSARS-CoV-2

Identifiers

PMID38206397
OpenAlexW4390743847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.